vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and FORRESTER RESEARCH, INC. (FORR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $101.1M, roughly 1.7× FORRESTER RESEARCH, INC.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -6.5%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 0.5%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Forrester Research, Inc. is a research and advisory firm working in research, consulting and events. Forrester’s clients include large global business, technology and consumer enterprises. The firm is headquartered in Cambridge, MA.
ESPR vs FORR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $101.1M |
| Net Profit | — | $-33.9M |
| Gross Margin | — | 56.7% |
| Operating Margin | 50.6% | -36.6% |
| Net Margin | — | -33.5% |
| Revenue YoY | 143.7% | -6.5% |
| Net Profit YoY | — | -7941.4% |
| EPS (diluted) | $0.32 | $-1.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $101.1M | ||
| Q3 25 | $87.3M | $94.3M | ||
| Q2 25 | $82.4M | $111.7M | ||
| Q1 25 | $65.0M | $89.9M | ||
| Q4 24 | $69.1M | $108.0M | ||
| Q3 24 | $51.6M | $102.5M | ||
| Q2 24 | $73.8M | $121.8M | ||
| Q1 24 | $137.7M | $100.1M |
| Q4 25 | — | $-33.9M | ||
| Q3 25 | $-31.3M | $-2.1M | ||
| Q2 25 | $-12.7M | $3.9M | ||
| Q1 25 | $-40.5M | $-87.3M | ||
| Q4 24 | — | $432.0K | ||
| Q3 24 | $-29.5M | $-5.8M | ||
| Q2 24 | $-61.9M | $6.3M | ||
| Q1 24 | $61.0M | $-6.7M |
| Q4 25 | — | 56.7% | ||
| Q3 25 | — | 60.0% | ||
| Q2 25 | — | 55.5% | ||
| Q1 25 | — | 55.9% | ||
| Q4 24 | — | 58.8% | ||
| Q3 24 | — | 60.5% | ||
| Q2 24 | — | 57.3% | ||
| Q1 24 | — | 54.9% |
| Q4 25 | 50.6% | -36.6% | ||
| Q3 25 | -11.4% | 4.7% | ||
| Q2 25 | 8.6% | 6.2% | ||
| Q1 25 | -34.0% | -97.5% | ||
| Q4 24 | -6.4% | -0.5% | ||
| Q3 24 | -31.0% | -0.7% | ||
| Q2 24 | 3.5% | 9.3% | ||
| Q1 24 | 52.5% | -9.3% |
| Q4 25 | — | -33.5% | ||
| Q3 25 | -35.9% | -2.3% | ||
| Q2 25 | -15.4% | 3.5% | ||
| Q1 25 | -62.2% | -97.1% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | -57.2% | -5.7% | ||
| Q2 24 | -83.9% | 5.2% | ||
| Q1 24 | 44.3% | -6.7% |
| Q4 25 | $0.32 | $-1.75 | ||
| Q3 25 | $-0.16 | $-0.11 | ||
| Q2 25 | $-0.06 | $0.20 | ||
| Q1 25 | $-0.21 | $-4.62 | ||
| Q4 24 | $-0.14 | $0.02 | ||
| Q3 24 | $-0.15 | $-0.30 | ||
| Q2 24 | $-0.33 | $0.33 | ||
| Q1 24 | $0.34 | $-0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $63.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $126.5M |
| Total Assets | $465.9M | $404.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $63.3M | ||
| Q3 25 | $92.4M | $65.1M | ||
| Q2 25 | $86.1M | $67.8M | ||
| Q1 25 | $114.6M | $75.6M | ||
| Q4 24 | $144.8M | $56.1M | ||
| Q3 24 | $144.7M | $62.8M | ||
| Q2 24 | $189.3M | $58.9M | ||
| Q1 24 | $226.6M | $61.4M |
| Q4 25 | $-302.0M | $126.5M | ||
| Q3 25 | $-451.4M | $157.7M | ||
| Q2 25 | $-433.5M | $159.5M | ||
| Q1 25 | $-426.2M | $147.4M | ||
| Q4 24 | $-388.7M | $229.5M | ||
| Q3 24 | $-370.2M | $234.3M | ||
| Q2 24 | $-344.2M | $237.1M | ||
| Q1 24 | $-294.3M | $230.9M |
| Q4 25 | $465.9M | $404.0M | ||
| Q3 25 | $364.0M | $414.2M | ||
| Q2 25 | $347.1M | $436.0M | ||
| Q1 25 | $324.0M | $439.8M | ||
| Q4 24 | $343.8M | $503.9M | ||
| Q3 24 | $314.1M | $505.3M | ||
| Q2 24 | $352.3M | $524.2M | ||
| Q1 24 | $373.1M | $555.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $-3.2M |
| Free Cash FlowOCF − Capex | — | $-4.3M |
| FCF MarginFCF / Revenue | — | -4.2% |
| Capex IntensityCapex / Revenue | 0.0% | 1.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $18.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $-3.2M | ||
| Q3 25 | $-4.3M | $1.2M | ||
| Q2 25 | $-31.4M | $-3.6M | ||
| Q1 25 | $-22.6M | $26.7M | ||
| Q4 24 | $-35.0M | $-1.8M | ||
| Q3 24 | $-35.3M | $264.0K | ||
| Q2 24 | $-7.2M | $-2.9M | ||
| Q1 24 | $53.8M | $611.0K |
| Q4 25 | — | $-4.3M | ||
| Q3 25 | — | $524.0K | ||
| Q2 25 | — | $-4.2M | ||
| Q1 25 | — | $26.1M | ||
| Q4 24 | — | $-2.5M | ||
| Q3 24 | $-35.5M | $-223.0K | ||
| Q2 24 | $-7.3M | $-3.7M | ||
| Q1 24 | $53.8M | $-815.0K |
| Q4 25 | — | -4.2% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | -3.8% | ||
| Q1 25 | — | 29.0% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | -68.7% | -0.2% | ||
| Q2 24 | -9.9% | -3.1% | ||
| Q1 24 | 39.0% | -0.8% |
| Q4 25 | 0.0% | 1.1% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.0% | 0.7% | ||
| Q4 24 | 0.0% | 0.6% | ||
| Q3 24 | 0.3% | 0.5% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 0.1% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.93× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -4.24× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.46× | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
